Nimotuzumab in Advanced Cervical Cancer: Safety and Efficacy Profile

Ruiz, L. Boronat; Sayly, Alfonso; Sánchez, Yamilka; Elena, Viada Carmen; Ramon, O.; Troche, Mayelin; Cepeda, M. Soledad; Rosa, Vals Ana; Cabrera, Leticia; Gorte, Annia; Maira, Batista Delmis; Milagros, Domenech; García, V.; Ramos, M C; Ramos, Suzarte Mayra

doi:10.23937/2643-4563/1710016

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The humanized mAb nimotuzumab directed against EGFR has been demonstrated a therapeutic efficacy, with increased survival in patients with persistent, recurrent or advanced-stage cervical cancer used as monotherapy [5] [6]. On the other hand, the CIMAvax EGE vaccine has shown therapeutic efficacy in patients with non-small cell lung tumors (NSCLC) [7], due to its capacity to develop anti EGF antibodies able to reduce circulating EGF concentrations by increasing the antibody titer in treated patients.…”

Section: Introductionmentioning

confidence: 99%

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>&reg;</sup> Therapeutic Vaccine

Ruiz-Lorente¹,

Sayly²,

Santiesteban³

et al. 2021

JCT

View full text Add to dashboard Cite

Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence, principally from epithelial origen. The high expression of EGFR in this tumor leads to the search for therapeutic alternatives. An Expanded Access Clinical Program was carried out in parallel groups, randomized, multicenter and prospective study, to evaluate the survival of patients with advanced cervical carcinoma, without therapeutic alternative, who would be treated with the therapeutic vaccine CIMAvax-EGF®, the humanized mAb nimotuzumab or the combination of both products, which targeted EGF and EGFR respectively. The patients were included between 2008 and 2010 with a more than five years follow-up. The results show that the serious adverse events related to the experimental treatments were 0.9%; 1.1% and 2.6% and a median ITT survival of 9.1, 23.5, and 16.3 months for CIMAvax-EGF®, nimotuzumab and the combination of both, respectively. Thus fulfilling the hypothesis of safety and efficacy proposed in the investigation was achieved. The three therapeutic regimens achieved overall survival rates greater than

show abstract

Section: Introductionmentioning

confidence: 99%

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>&reg;</sup> Therapeutic Vaccine

Ruiz-Lorente¹,

Sayly²,

Santiesteban³

et al. 2021

JCT

View full text Add to dashboard Cite

show abstract

Nimotuzumab in Advanced Cervical Cancer: Safety and Efficacy Profile

Cited by 1 publication

References 22 publications

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>&reg;</sup> Therapeutic Vaccine

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>&reg;</sup> Therapeutic Vaccine

Contact Info

Product

Resources

About

Nimotuzumab in Advanced Cervical Cancer: Safety and Efficacy Profile

Cited by 1 publication

References 22 publications

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF&lt;sup&gt;&amp;reg;&lt;/sup&gt; Therapeutic Vaccine

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF&lt;sup&gt;&amp;reg;&lt;/sup&gt; Therapeutic Vaccine

Contact Info

Product

Resources

About

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>®</sup> Therapeutic Vaccine

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF<sup>®</sup> Therapeutic Vaccine